Murray Stahl's RPRX Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 353,361 shares of Royalty Pharma plc (RPRX) worth $13.65 M, representing 0.18% of the portfolio. First purchased in 2021-Q1, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Murray Stahl has maintained a strategic position in RPRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2021, adding 163,492 shares. Largest reduction occurred in Q4 2023, reducing 70,565 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Royalty Pharma plc (RPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Royalty Pharma plc (RPRX) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -1,324 | Reduce 0.37% | 353,361 | $38.64 |
| Q3 2025 | +1,214 | Add 0.34% | 354,685 | $35.28 |
| Q2 2025 | +23,901 | Add 7.25% | 353,471 | $36.03 |
| Q1 2025 | +10,394 | Add 3.26% | 329,570 | $31.13 |
| Q4 2024 | +90,380 | Add 39.50% | 319,176 | $25.51 |
| Q3 2024 | +12 | Add 0.01% | 228,796 | $28.29 |
| Q2 2024 | +28,496 | Add 14.23% | 228,784 | $26.37 |
| Q1 2024 | -16,402 | Reduce 7.57% | 200,288 | $30.37 |
| Q4 2023 | -70,565 | Reduce 24.57% | 216,690 | $28.09 |
| Q3 2023 | -46,414 | Reduce 13.91% | 287,255 | $27.14 |
| Q2 2023 | -39,451 | Reduce 10.57% | 333,669 | $30.74 |
| Q1 2023 | -26,760 | Reduce 6.69% | 373,120 | $36.03 |
| Q4 2022 | -8,666 | Reduce 2.12% | 399,880 | $39.52 |
| Q3 2022 | -45,010 | Reduce 9.92% | 408,546 | $40.18 |
| Q2 2022 | +62,638 | Add 16.02% | 453,556 | $42.04 |
| Q1 2022 | +108,381 | Add 38.36% | 390,918 | $38.96 |
| Q4 2021 | +42,209 | Add 17.56% | 282,537 | $39.85 |
| Q3 2021 | +27,071 | Add 12.69% | 240,328 | $36.14 |
| Q2 2021 | +163,492 | Add 328.53% | 213,257 | $40.99 |
| Q1 2021 | +49,765 | New Buy | 49,765 | $43.63 |
Murray Stahl's Royalty Pharma plc Investment FAQs
Murray Stahl first purchased Royalty Pharma plc (RPRX) in Q1 2021, acquiring 49,765 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Royalty Pharma plc (RPRX) for 20 quarters since Q1 2021.
Murray Stahl's largest addition to Royalty Pharma plc (RPRX) was in Q2 2021, adding 213,257 shares worth $8.74 M.
According to the latest 13F filing for Q4 2025, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 353,361 shares of Royalty Pharma plc (RPRX), valued at approximately $13.65 M.
As of the Q4 2025 filing, Royalty Pharma plc (RPRX) represents approximately 0.18% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in Royalty Pharma plc (RPRX) was 453,556 shares, as reported at the end of Q2 2022.